Want to see CGTX full AI Analyst Report?
CGTX Stock Chart & Stats
$1.03
-$0.04(-4.24%)
At close: 4:00 PM EDT
$1.03
-$0.04(-4.24%)
Day’s Range― - ―
52-Week Range$0.55 - $1.93
Previous CloseN/A
Volume451.33K
Average Volume (3M)523.90K
Market Cap
$69.40M
Enterprise Value$70.05M
Total Cash (Recent Filing)$34.01M
Total Debt (Recent Filing)$511.00K
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Nov 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding95,093,740
10 Day Avg. Volume744,069
30 Day Avg. Volume523,902
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-542.98
Enterprise Value/Ebitda-4.24
Forecast
1Y Price Target
$3.00Price Target Upside191.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces fixed financial obligations and preserves flexibility while Cognition funds clinical development. Positive equity provides a capital base, allowing management to pursue programs without the added pressure of substantial debt service or refinancing demands.
Narrowing Net LossesThe substantial improvement in net loss indicates that spending or operating discipline has strengthened over time, even though the company remains unprofitable. If sustained, this trajectory could extend the runway available for clinical execution and reduce the pace of capital consumption.
Reduced Cash BurnA lower absolute cash burn rate is constructive for a clinical-stage company because it can preserve resources for research and trials for longer. Continued improvement would reduce the frequency or size of future financing needs, although cash flow remains negative.
Bears Say
No Recurring Product RevenueThe absence of product revenue means Cognition has not yet established a commercial engine to fund operations internally. Progress therefore remains dependent on successful development and eventual commercialization of investigational candidates rather than diversified recurring sales.
Persistent Cash OutflowsOngoing negative operating and free cash flow requires continued use of cash reserves or external capital to support operations and clinical programs. This dependence can constrain strategic flexibility and makes long-term execution more sensitive to the company’s ability to raise funds.
Ongoing UnprofitabilityMaterially negative operating earnings show that current activities consume value rather than generate sustainable returns. Until development programs produce revenue or another durable income source emerges, continued losses will weigh on equity and limit internally funded investment capacity.
Cognition Therapeutics News
CGTX FAQ
What was Cognition Therapeutics’s price range in the past 12 months?
Cognition Therapeutics lowest stock price was $0.55 and its highest was $1.93 in the past 12 months.
What is Cognition Therapeutics’s market cap?
Cognition Therapeutics’s market cap is $69.40M.
When is Cognition Therapeutics’s upcoming earnings report date?
Cognition Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 30 days.
How were Cognition Therapeutics’s earnings last quarter?
Cognition Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.063 by $0.023.
Is Cognition Therapeutics overvalued?
According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued.
Does Cognition Therapeutics pay dividends?
Cognition Therapeutics does not currently pay dividends.
What is Cognition Therapeutics’s EPS estimate?
Cognition Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Cognition Therapeutics have?
Cognition Therapeutics has 95,093,740 shares outstanding.
What happened to Cognition Therapeutics’s price movement after its last earnings report?
Cognition Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.063. Following the earnings report the stock price went down -4.425%.
Which hedge fund is a major shareholder of Cognition Therapeutics?
Currently, no hedge funds are holding shares in CGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cognition Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (191.26% Upside)
$3.00 (191.26% Upside)
Blogger Sentiment
Bullish
CGTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.59%
12-Months-Change
Fundamentals
Return on Equity
-50.17%
Trailing 12-Months
Asset Growth
98.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cognition Therapeutics
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
CGTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(191.26% Upside)
Technical Analysis
Tonix Pharma
―
Adicet Bio
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
10.17% Insiders
4.06% Mutual Funds
4.52% Other Institutional Investors
77.43% Public Companies and
Individual Investors